Payment overview · 2025
General Payments
$29.19
1 reported records · 1 companies
Healthcare provider profile · identity verified
Carla Mitchell Armstrong, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · TYLERTOWN, MS · NPI 1346238359
Verified facts
What the public records show
CMS Open Payments records show Carla Mitchell Armstrong, M.D. received $29.19 in general payments during 2025 across 1 reported records.
Otsuka America Pharmaceutical, Inc. accounted for 100.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 1 associated product.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABILIFY MAINTENA as an associated drug or biological on 27924 records involving 10497 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Abilify Maintena by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $29.19 | 100.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $29.19 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $29.19 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | ABILIFY MAINTENA open payments reported associated product |
CMS Open Payments — General Payments 27924 supporting records · 10497 recipient NPIs · example record 1227267721 |
Abilify Maintena · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 759 | 119 |
| Atorvastatin Calcium | Atorvastatin Calcium | 556 | 111 |
| Pantoprazole Sodium | Pantoprazole Sodium | 372 | 66 |
| Gabapentin | Gabapentin | 370 | 82 |
| Levothyroxine Sodium | Levothyroxine Sodium | 355 | 34 |
| Potassium Chloride | Potassium Chloride | 344 | 70 |
| Furosemide | Furosemide | 320 | 77 |
| Mirtazapine | Mirtazapine | 289 | 29 |
| Clopidogrel | Clopidogrel Bisulfate | 271 | 43 |
| Alprazolam | Alprazolam | 256 | 32 |
| Carvedilol | Carvedilol | 227 | 32 |
| Hydralazine Hcl | Hydralazine Hcl | 227 | 30 |
| Losartan Potassium | Losartan Potassium | 219 | 50 |
| Metformin Hcl | Metformin Hcl | 216 | 51 |
| Metoprolol Succinate | Metoprolol Succinate | 203 | 39 |
| Omeprazole | Omeprazole | 197 | 30 |
| Lisinopril | Lisinopril | 190 | 22 |
| Donepezil Hcl | Donepezil Hcl | 188 | 33 |
| Memantine Hcl | Memantine Hcl | 185 | 21 |
| Hydrochlorothiazide | Hydrochlorothiazide | 178 | 38 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 159 | 64 |
| Meloxicam | Meloxicam | 156 | 25 |
| Eliquis | Apixaban | 155 | 14 |
| Escitalopram Oxalate | Escitalopram Oxalate | 149 | 20 |
| Allopurinol | Allopurinol | 145 | 16 |
| Januvia | Sitagliptin Phosphate | 145 | 19 |
| Pravastatin Sodium | Pravastatin Sodium | 139 | 14 |
| Clonidine Hcl | Clonidine Hcl | 131 | 23 |
| Glimepiride | Glimepiride | 129 | 28 |
| Benazepril Hcl | Benazepril Hcl | 126 | 28 |
| Buspirone Hcl | Buspirone Hcl | 126 | 22 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 125 | 40 |
| Trazodone Hcl | Trazodone Hcl | 116 | 19 |
| Fluticasone Propionate | Fluticasone Propionate | 110 | 32 |
| Myrbetriq | Mirabegron | 107 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 104 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 99 | 20 |
| Sertraline Hcl | Sertraline Hcl | 97 | 11 |
| Tizanidine Hcl | Tizanidine Hcl | 96 | 39 |
| Quetiapine Fumarate | Quetiapine Fumarate | 93 | 12 |
| Glipizide | Glipizide | 92 | 12 |
| Metoprolol Tartrate | Metoprolol Tartrate | 90 | 15 |
| Benztropine Mesylate | Benztropine Mesylate | 85 | suppressed |
| Clonazepam | Clonazepam | 82 | 13 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 81 | suppressed |
| Linzess | Linaclotide | 81 | 22 |
| Tamsulosin Hcl | Tamsulosin Hcl | 77 | 22 |
| Famotidine | Famotidine | 74 | 16 |
| Ezetimibe | Ezetimibe | 73 | 12 |
| Haloperidol | Haloperidol | 73 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 72 | 13 |
| Spironolactone | Spironolactone | 71 | 15 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 70 | 25 |
| Simvastatin | Simvastatin | 68 | 17 |
| Tradjenta | Linagliptin | 68 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 68 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 66 | 11 |
| Atenolol | Atenolol | 66 | suppressed |
| Amoxicillin | Amoxicillin | 64 | 40 |
| Colchicine | Colchicine | 62 | 14 |
| Azithromycin | Azithromycin | 61 | 54 |
| Meclizine Hcl | Meclizine Hcl | 60 | 27 |
| Ibuprofen | Ibuprofen | 58 | 25 |
| Lactulose | Lactulose | 58 | suppressed |
| Cilostazol | Cilostazol | 57 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 56 | 15 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 53 | 13 |
| Levetiracetam | Levetiracetam | 53 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 52 | suppressed |
| Lovastatin | Lovastatin | 52 | 13 |
| Xarelto | Rivaroxaban | 52 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 47 | 14 |
| Ramipril | Ramipril | 47 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 46 | 23 |
| Methylprednisolone | Methylprednisolone | 45 | 32 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 45 | 12 |
| Pioglitazone Hcl | Pioglitazone Hcl | 44 | 11 |
| Promethazine Hcl | Promethazine Hcl | 44 | 11 |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 42 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 41 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 41 | 11 |
| Ondansetron Odt | Ondansetron | 41 | 23 |
| Prednisone | Prednisone | 41 | 24 |
| Lorazepam | Lorazepam | 40 | suppressed |
| Ozempic | Semaglutide | 40 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 40 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 39 | 16 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 39 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 38 | 13 |
| Celecoxib | Celecoxib | 34 | suppressed |
| Finasteride | Finasteride | 34 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 34 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 34 | 14 |
| Phenobarbital | Phenobarbital | 33 | suppressed |
| Fluconazole | Fluconazole | 32 | 20 |
| Naproxen | Naproxen | 32 | 12 |
| Levofloxacin | Levofloxacin | 31 | 27 |
| Ropinirole Hcl | Ropinirole Hcl | 30 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 29 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 29 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 29 | suppressed |
| Latanoprost | Latanoprost | 29 | suppressed |
| Dexamethasone | Dexamethasone | 28 | 25 |
| Glyxambi | Empagliflozin/Linagliptin | 28 | suppressed |
| Novolog Flexpen | Insulin Aspart | 28 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Lubiprostone | Lubiprostone | 27 | suppressed |
| Mupirocin | Mupirocin | 27 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 27 | suppressed |
| Metolazone | Metolazone | 26 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 26 | 14 |
| Penicillin V Potassium | Penicillin V Potassium | 26 | 13 |
| Pregabalin | Pregabalin | 26 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 25 | suppressed |
| Clonidine | Clonidine | 25 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 25 | 22 |
| Minoxidil | Minoxidil | 25 | suppressed |
| Olanzapine | Olanzapine | 25 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 24 | 21 |
| Alendronate Sodium | Alendronate Sodium | 23 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 23 | 22 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 23 | suppressed |
| Novolin R | Insulin Regular, Human | 22 | suppressed |
| Sucralfate | Sucralfate | 22 | suppressed |
| Cephalexin | Cephalexin | 21 | 18 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 20 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Valsartan | Valsartan | 19 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 18 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 18 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 18 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 18 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 18 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 18 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 17 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 17 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 16 | 12 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Glipizide Er | Glipizide | 16 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 15 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 15 | suppressed |
| Entresto | Sacubitril/Valsartan | 15 | suppressed |
| Novolog | Insulin Aspart | 15 | suppressed |
| Torsemide | Torsemide | 15 | suppressed |
| Carbamazepine | Carbamazepine | 14 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 14 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 14 | suppressed |
| Nitroglycerin | Nitroglycerin | 14 | 11 |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 14 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 14 | suppressed |
| Carisoprodol | Carisoprodol | 13 | suppressed |
| Diclofenac Sodium Er | Diclofenac Sodium | 13 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 13 | suppressed |
| Jardiance | Empagliflozin | 13 | suppressed |
| Sotalol | Sotalol Hcl | 13 | suppressed |
| Abilify Maintena | Aripiprazole | 12 | suppressed |
| Felodipine Er | Felodipine | 12 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 12 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 12 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 12 | suppressed |
| Travoprost | Travoprost | 12 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 11 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 11 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
| Fondaparinux Sodium | Fondaparinux Sodium | 11 | suppressed |
| Glyburide | Glyburide | 11 | suppressed |
| Levemir Flexpen | Insulin Detemir | 11 | suppressed |
| Methocarbamol | Methocarbamol | 11 | suppressed |
| Suboxone | Buprenorphine Hcl/Naloxone Hcl | 11 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $29.19 · 1 records | Otsuka America Pharmaceutical, Inc. | REXULTI | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Otsuka America Pharmaceutical, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error